Please note, some trial-specific information on this page is sourced from clinicaltrials.gov.
About
Trial summary
TYPEINTERVENTIONAL
PHASE
Phase
Clinical trials are done in different phases (0-4). Each phase provides important information about the drug. If a drug does not pass a particular phase, it cannot progress to the next phase. Visit the About Clinical Trials page to learn more.
PHASE1
CONDITION
Tumors
Lymphoma
INTERVENTIONS
Interventions
The drug, device, or procedure being tested.
DRUG:CNF2024
CNF2024 capsules administered orally following 2 schedules:
* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or
* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.
ENROLLMENT
Enrollment
The number of participants needed to take part in this trial.
70 participants
(ACTUAL)
18 Years and Above
(ADULT, OLDER ADULT)
LOCATIONS4
Key dates
Key dates
When the trial is conducted - from the date the first participant is enrolled to the date of the last participants's final visit.
Results from this trial have been made available. Some information may be redacted (edited) to protect privacy, publication rights, and confidential commercial information. To review the information please visit biogentrialtransparency.com.
PDF
Clinical trial registers
Clinical trial registers, like clinicaltrials.gov, provide information about registered clinical trials.
Publishing results for completed clinical trials on clinical trial registers help us share information about our clinical research. The results we publish here are written for healthcare professionals.
Please contact a clinical trial site directly to learn more about the trial. If no contact details are available, or for general inquiries, please contact the Biogen Clinical Trial Center.
